Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Transcept Pharmaceuticals
January 19, 2015
2014 sets post-crash venture record, but you ain’t seen nothing yet
March 25, 2013
Oblivion beckons for Remodulin as FDA again says no
January 03, 2013
Pharma data news over the Christmas period
December 06, 2012
Investors kick Chelsea after it trips on its Northera data again
February 07, 2012
Merck’s new sleep drug has soporific effect on markets
December 13, 2011
Alexza's failure to win broad backing for Adasuve could be last gasp
November 24, 2011
Intermezzo approval not the end of Transcept thriller
November 11, 2011
Nabi's demise and cash could attract IPO hopefuls
September 19, 2011
Transcept and Vivus hoping to buck the trend with another approval chance
September 02, 2011
PDUFA renewal plans include longer reviews and more meetings
July 13, 2011
Intermezzo disappointment another rude awakening for Transcept
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 29, 2021
Biopharma Quarterly Round Up (Q3 2021)
November 16, 2021
Covid Round Up (2021)
Editor's Picks
November 22, 2021
The bubble bursts for biotech stocks
November 08, 2021
Ash 2021 preview – as competition grows Autolus monetises
November 23, 2021
Ash 2021 late-breakers enable neat comparisons
November 04, 2021
What Novartis could buy with its windfall
November 16, 2021
Fate buries bad data and moves on
